Pay in 4 interest-free payments of $23.75 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Myocardial remodeling in diabetic cardiomyopathy associated with cardiac mast cell activation
CCOC(=O)[C@H](CCC1C=CC=CC=1)N[C@H]1CCC2=CC=CC=C2N(CC(O)=O)C1=O
CAS Number: 882257-11-6
[2H]C([2H])([2H])N(C[C@H]1CC2=CC(OC)=C(C=C21)OC)CCCN1CCC2=CC(OC)=C(C=C2CC1=O)OC
Salirasib reduces Rheb in TSC2-null cells and TSC2 expression rescues the cells from the inhibitory effect of Salirasib
BI-D1870 - CAS# 501437-28-1 Catalog No.:M11147-2 Myocardial remodeling in diabetic cardiomyopathyBI D1870 is a potent and specific RSK inhibitor (the p90 ribosomal S6 kinase), which inhibits RSK1, RSK2, RSK3 and RSK4 in vitro with an IC50 of 1030 nM. BI D1870 exhibited a dose responsive antiproliferative effect on OSCC cells with relative sparing of normal human oral keratinocytes. The compound inhibited the downstream RSK target YB 1 and caused apoptosis. In addition, BI D1870 also induced G2 M arrest by modulating the expression of p21 and